Buy Kalytera Therapeutics for a 328 per cent return: Echelon Wealth

California-based drug developer Kalytera Therapeutics (Kalytera Therapeutics Stock Quote, Chart TSXV:KALY) may be facing competitive headwinds going forward but the markets have yet to recognize the value in the company’s efforts so far, according to analyst Douglas Loe of Echelon Wealth Partners, who on Thursday reiterated his “Speculative Buy” rating and $0.30 target price.

Cannabinoid-focused drug development firm Kalytera made two announcements this week, one being the closing of a C$787,500 private placement and the other being the start of a new Phase I CBD clinical initiatives exploring food effects and cardiovascular side effect profile and drug-drug interactions.

Loe calls the new Phase I CBD testing conventional and not overly impactful on his investment thesis.

“Our investment thesis on KALY continues to balance two major offsetting risk factors, with highly positive interim Phase II GvHD data already available that greatly mitigates clinical risk for CBD’s utility in that market but with lingering financial risk that the new convertible debt only partially solves and only as a bridge to supporting the aforementioned Phase II GvHD program to final data and no further,” says Loe.

“We stand by our view that capital markets are not fully recognizing the value embedded in Kalytera’s Phase II accomplishments already (including the 2015 48-patient Phase II GvHD trial that was not funded by Kalytera itself) or in CBD’s prospects in this distinct medical market for which Kalytera has unique patent-protected development rights. Thera are certainly competitive headwinds on the horizon and Kalytera is not the only drug developer targeting GvHD, nor is it close to being the most advanced clinical GvHD developer we see on the horizon,” he says.

Loe is projecting 2023 revenue and EBITDA estimates of $5.0 million and negative $3.8 million, respectively, and 2024 revenue and EBITDA of $26.4 million and $17.4 million, respectively. His target price projects a 12-month return of 328 per cent at the time of publication.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: kaly
Jayson MacLean

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

Recent Posts

Sabio has 400% upside, Eight Capital says

Following the company's fourth quarter results, Eight Capital analyst Kiran Sritharan has maintained his "Buy" rating on Sabio Holdings (Sabio… [Read More]

2 days ago

Is SNAP a buy right now?

He feels the company made forward progress in its recent quarterly results, but Roth MKM analyst Rohit Kulkarni wants to… [Read More]

2 days ago

Bombardier wins price target raise at Desjardins

Following the company's first quarter results, Desjardins analyst Benoit Poirier has raised his price target on Bombardier (Bombardier Stock Quote,… [Read More]

3 days ago

Rogers is an undervalued stock, RBC says

With the integration of Shaw Communications underway, RBC analyst Drew McReynolds says Rogers Communications (Rogers Communications Stock Quote, Chart, News,… [Read More]

4 days ago

Tornado Global Hydrovacs is still a double, Beacon says

Following fourth quarter results he describes as "stronger than expected", Beacon Securities analyst Russell Stanley has raised his price target… [Read More]

4 days ago

Sell your Molson Coors stock, Citi says

Ahead if its first quarter results, Citi analyst Filippo Falorni says there is not much to like about Molson Coors… [Read More]

5 days ago